Key Considerations for Insmed Investors

By Ken Smith • Wednesday, April 02 09:54 • Permanent Link

More and more people are talking about Insmed over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $71.44? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Insmed has moved 160.1% over the last year, and the S&P 500 logged a change of 8.1%
INSM has an average analyst rating of buy and is -25.19% away from its mean target price of $95.49 per share
Its trailing earnings per share (EPS) is $-5.57
Insmed has a trailing 12 month Price to Earnings (P/E) ratio of -12.8 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $-4.23 and its forward P/E ratio is -16.9
The company has a Price to Book (P/B) ratio of 44.9 in contrast to the S&P 500's average ratio of 4.74
Insmed is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
The company has a free cash flow of $-418300384, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.